Gentronix has unveiled its genotoxicity contract testing service at the Society of Toxicology Annual Toxexpo in Baltimore.
The service provides an alternative method for the rapid and accurate evaluation of compound genotoxic liability with no disruption to drug development laboratories.
Accurate detection of genotoxic hazard early in drug discovery allows problem compounds to be rejected or modified to reduce toxicity.
This reduces failure during late stage preclinical safety assessment, where resources are already committed and there is increased reliance on animal studies to resolve conflicting data.
The service from Gentronix is designed to address the need for accurate and cost-effective genotoxicity testing.
Studies can be performed on one to more than 1,000 test compounds, and can also be performed in the presence of metabolising enzymes (from S9) to detect potentially genotoxic metabolites of compounds.
The regulatory in vitro genotoxicity tests are all carried out with and without this metabolic activation system.
Only a small quantity of compound is required; approximately 10mg pre-weighed material per compound analysed allows testing up to typically 1mg/ml.
Full test reports, including supporting documentation to assist with data interpretation, are typically available within just two weeks of receipt of compounds.
Gentronix's in-house expertise allows the assay to be tailored according to individual testing requirements.
Protocols can also be adapted for compounds with diverse physicochemical properties.
